Item 8.01 Other Events.
On December 7, 2012, Cytokinetics, Inc. issued a press release announcing a
platform presentation of pharmacokinetic data and
pharmacokinetic/pharmacodynamic analyses from three previously-reported clinical
trials of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) at the
23rd International Symposium on ALS and Motor Neurone Diseases (ALS/MND) in
Chicago, IL. Tirasemtiv is the lead drug candidate that has emerged from the
company's skeletal muscle contractility program. Tirasemtiv selectively
activates the fast skeletal muscle troponin complex by increasing its
sensitivity to calcium, which increases skeletal muscle force in response to
neuronal input. In preclinical studies, this mechanism has been shown to delay
the onset and reduce the degree of muscle fatigue.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K, and is incorporated herein by reference.
Top of the Form
Add
CYTK to Portfolio
Set Alert
Email to a
Friend